New drug duo targets advanced gynecologic cancers in early trial
NCT ID NCT07424664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, becotatug vedotin and zimberelimab, in 30 people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have already tried at least one standard therapy. The trial is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
- Blood test may spot returning cervical cancer before symptoms appear
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- Immunotherapy combo shows promise for advanced cervical cancer
- New combo therapy shows promise for Tough-to-Treat cervical cancer
- New combo therapy offers hope for advanced cervical cancer patients